Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-03-12

Clinical Trial Update: Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of SR58611A in generalized anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SR58611A

Snippet

Sponsor: Sanofi | Conditions: Anxiety Disorder | Phase 3 | Status: COMPLETED